CT041
- Generic Name
- CT041
- Drug Type
- Biotech
- Background
CT041 is an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2).
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2023-06-20
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- CARsgen Therapeutics Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05911217
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China
🇨🇳Hunan Provincial People's Hospital, Changsha, Hunan, China
🇨🇳Ruijin Hospital, affiliated to Shanghai Jiaotong University, school of medicine, Shanghai, Shanghai, China
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
- Conditions
- Gastric AdenocarcinomaPancreatic CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- Drug: Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- CARsgen Therapeutics Co., Ltd.
- Target Recruit Count
- 192
- Registration Number
- NCT04581473
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers
- Conditions
- Gastric CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- CARsgen Therapeutics Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT04404595
- Locations
- 🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸UCSD, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.